Experimental drug offered to patients with rare gut condition
NCT ID NCT05232110
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study provides compassionate access to pozelimab for people with CD55-deficient protein-losing enteropathy, a rare condition where the gut leaks proteins. The goal is to offer an experimental treatment option when no other therapies are available. Participants receive the drug under close medical supervision.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: \- Exclusion Criteria: \-
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD55-deficient protein-losing enteropathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.